RxDoctor Payments Data

Christine Lerback, APRN

Family · Bandera, TXNPI 1003387184

Payments from drug & device makers

$2,669in general payments, 2019–2025

Across 212 payments — averaging $12.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$783
  • Otsuka America Pharmaceutical, Inc.$636
  • Johnson & Johnson$396
  • Avanir Pharmaceuticals, Inc.$213
  • Sumitomo Pharma America, Inc.$137
  • Neurocrine Biosciences, Inc.$103
  • plus $400 from 8 others

What the payments were for

  • Food & beverage$2,46792%
  • Education$2028%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,669 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$2,081,591
Medicare patients
398
Services billed
2,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate176$622,540
AustedoDeutetrabenazine32$206,489
Austedo XrDeutetrabenazine35$197,197
JardianceEmpagliflozin221$135,527
GemtesaVibegron170$84,527
EliquisApixaban113$80,283
XifaxanRifaximin16$52,194
Breo ElliptaFluticasone/Vilanterol103$43,681
OzempicSemaglutide35$33,585
TradjentaLinagliptin59$31,354
JanuviaSitagliptin Phosphate44$31,258
Paliperidone ErPaliperidone58$28,444
MyrbetriqMirabegron47$27,852
RexultiBrexpiprazole19$25,638
AptiomEslicarbazepine Acetate19$25,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$396$639,205204 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$783$403,68667 claims
Sumitomo Pharma America, Inc.Gemtesa$137$84,527170 claims
AbbVieVraylar, Linzess$49$43,04151 claims
Novo NordiskOzempic$14$33,58535 claims
Otsuka America Pharmaceutical, Inc.Rexulti$636$25,63819 claims
Sunovion Pharmaceuticals Inc.Aptiom$63$25,17019 claims
Scilex Pharmaceuticals Inc.Ztlido$63$19,50725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Bandera

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →